Objectif
Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis (MTB) infection. Effective prophylactic vaccination remains the key long-term strategy for combating TB. Continued belief in reaching this goal requires unrelenting innovation in the formulation and delivery of candidate vaccines. It is also based on the assumption, that the failure of recent human vaccine trials could have been due to a sub-optimal vaccine design and delivery, and therefore should not erode the key principle that a TB vaccine is an attainable target. This proposal focuses on mucosal vaccination, which has been considered in the past, but not implemented efficiently. The innovation of the proposal is focused on several important aspects of vaccine development and testing, including the use of novel technologies for vaccine delivery, novel ways of specific targeting of mucosal immune cells and tissues, the use of polypeptides incorporating early and latent MTB antigens and putative CD8+ T cell epitopes, and application of novel tools for identifying early predictors and correlates of vaccine-induced protection. The overall objective is to design a vaccine that will induce a broad-ranging immune response to MTB both systemically and in the mucosa of the lungs, and provide the currently missing links in protective immunity to this pathogen.
Champ scientifique
- natural sciencesbiological sciencesbiochemistrybiomolecules
- medical and health scienceshealth sciencesinfectious diseases
- medical and health sciencesbasic medicineimmunology
- medical and health sciencesclinical medicinepneumologytuberculosis
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugsvaccines
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
SW17 0RE London
Royaume-Uni
Voir sur la carte
Participants (13)
WC2R 2LS London
Voir sur la carte
17177 Stockholm
Voir sur la carte
36310 Vigo Pontevedra
Voir sur la carte
38126 Braunschweig
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
90127 Palermo
Voir sur la carte
NW1 0NH LONDON
Voir sur la carte
L’entreprise s’est définie comme une PME (petite et moyenne entreprise) au moment de la signature de la convention de subvention.
10691 Stockholm
Voir sur la carte
28006 Madrid
Voir sur la carte
00133 Roma
Voir sur la carte
08916 Badalona Barcelona
Voir sur la carte
LS2 7UE Leeds
Voir sur la carte
Maputo
Voir sur la carte
142 00 Praha 4
Voir sur la carte